Company Overview
Corvus Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company dedicated to developing product candidates that precisely target proteins critical to immune cell maturation and function within the United States. The company is situated within the Healthcare sector and specifically functions inside the Biotechnology industry, a landscape characterized by high-risk research and development aimed at creating novel therapeutics. The firm currently maintains a market capitalization of $1.10 billion and employs a workforce of 37 individuals to support its clinical development pipeline. These valuation and staffing figures indicate that the company is a mid-to-large cap entity relative to its specific employee base, suggesting a capital-intensive operational model typical of biotechnology firms where significant resources are allocated to clinical trials and product candidate advancement rather than broad-scale commercial sales operations.
Financial Health
The company reports a Net Income of $-15,283,000 for the trailing twelve months, while its EBITDA stands at $-42,866,000, and Revenue figures are listed as N/A. The substantial gap between the reported net income and the more negative EBITDA figure reveals a cost structure burdened by significant non-operating expenses or other comprehensive income/loss items that impact the bottom line beyond core operational earnings. Free Cash Flow is reported at $-46,856,876, indicating that the company is currently burning cash to fund its operations and development activities, which limits immediate financial flexibility but is common for clinical stage entities. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard metric for biotechnology companies that have not yet achieved commercial product sales or have revenue that does not cover direct costs in the traditional sense. On the balance sheet, the company holds $56.75M in Cash against $937,000 in Debt, resulting in a Debt to Equity ratio of 1.53. Despite the relatively low absolute debt figure, the high debt-to-equity ratio suggests a leveraged capital structure where equity is diluted relative to obligations, though the substantial cash reserve provides a significant buffer against short-term debt servicing. The Current Ratio is 6.21, which indicates strong short-term liquidity, meaning the company possesses more than six times the current assets necessary to cover its current liabilities. Return on Equity is -32.6% and Return on Assets is -38.4%, metrics that reveal that management is currently generating negative returns on the capital invested by shareholders and utilized in assets, reflecting the pre-commercialization nature of the business model.
Valuation Assessment
The Trailing P/E ratio is N/A due to the lack of positive earnings, while the Forward P/E is -15.61, a negative figure that implies the market expects earnings to remain negative in the near future or that valuation is based on anticipated future profitability rather than current performance. The Price to Book ratio is 16.06, indicating that the stock is trading at a significant premium over its net asset value, a valuation characteristic often seen in biotechnology firms with high-growth potential or valuable intellectual property. The Price to Sales ratio is N/A, and the EV/EBITDA is -24.46, suggesting that traditional earnings-based valuation multiples are not applicable and that alternative metrics must be used to assess value based on enterprise value relative to cash generation capabilities. The stock has traded within a 52-week range between a low of $2.54 and a high of $26.95; without a specific current price provided in the facts, the position relative to this range is defined by this wide dispersion which reflects high market volatility. The Beta is 0.84, which indicates that the stock's price volatility is slightly lower than the broader market average, suggesting it may be less sensitive to general market swings than the average large-cap stock despite the inherent risks of the biotechnology sector.
Growth & Income
Revenue Growth and Earnings Growth rates are both listed as N/A, which prevents a direct comparison of growth rates between the top line and the bottom line. In the absence of historical growth data, it is not possible to determine if earnings are growing faster or slower than revenue based on the available facts. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This 0.0% payout ratio confirms that the company retains all of its earnings and cash reserves to reinvest into research, development, and clinical trials rather than paying dividends to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential for future commercial success and capital appreciation, as the company foregoes current income distribution to fund its clinical stage product candidates.